Table 4. AEs occurring in the 75 patients receiving BVD.
| AEs | Grade 1–2, n (%) | Grade 3–4, n (%) | Grade 5, n (%) |
|---|---|---|---|
| Anaemia | 24 (32) | 9 (12) | |
| Neutropenia | 16 (21) | 14 (18.5) | |
| Thrombocytopenia | 19 (25) | 23 (30.5) | |
| Infections | 8 (10.5) | 6 (8) | 3 (4) |
| Peripheral neuropathy | 18 (24) | 6 (8) | |
| Cardiac toxicity | 3 (4) | 1 (1) | 2 (2.5) |
| Liver toxicity | 2 (2.5) | 1 (1) | |
| Gastrointestinal toxicity | 9 (12) | 4 (5) | |
| Fatigue | 17 (23) | 2 (2.5) | |
| DVT | 2 (2.5) | 2 (2.5) |
Abbreviations: BVD, bendamustine plus bortezomib and dexamethasone; DVT, deep vein thrombosis.